http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th
-
Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th
-
Savara Reports Third Quarter 2018 Financial Results and Provides Business Update
-
Savara Reports Third Quarter 2018 Financial Results and Provides Business Update
-
Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018
-
Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018
-
Savara (SVRA) Reports Complete Enrollment in Molgradex OPTIMA Clinical Study for Treatment of NTM
-
Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM
-
Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM
-
Savara (SVRA) Reports Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
-
Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
-
Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
-
Savara Provides Enrollment Update on Molgradex Impala and OPTIMA Clinical Studies and Reaffirms Guidance for Topline Data
-
Savara Provides Enrollment Update on Molgradex Impala and OPTIMA Clinical Studies and Reaffirms Guidance for Topline Data
-
BioTime (BTX) Names Brian Culley as CEO
-
BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
-
BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
-
Savara Becomes Inaugural Foundation Sponsor of the PAP Foundation
-
Savara Becomes Inaugural Foundation Sponsor of the PAP Foundation
-
Savara Reports Second Quarter 2018 Financial Results and Provides Positive Business Update
-
Savara Reports Second Quarter 2018 Financial Results and Provides Positive Business Update
-
Savara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018
-
Savara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018
-
Savara Provides Positive Update on Development and Commercial Preparations of Molgradex, Including Expansion into NTM In CF
-
Savara Provides Positive Update on Development and Commercial Preparations of Molgradex, Including Expansion into NTM In CF
-
Savara to Ring Nasdaq Stock Market Opening Bell on July 23rd
-
Savara to Ring Nasdaq Stock Market Opening Bell on July 23rd
-
Savara Joins Russell 3000® Index
-
Savara Joins Russell 3000® Index
-
Savara to Present at JMP Securities 2018 Life Sciences Conference on June 20th
-
Savara to Present at JMP Securities 2018 Life Sciences Conference on June 20th
-
Savara (SVRA) Announces Update on Two Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor
-
Savara Provides Update on Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria Infection
-
Savara Provides Update on Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria Infection
-
UPDATE -- Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 15th
-
UPDATE -- Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 15th
-
Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 17th
-
Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 17th
-
Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 17th
-
Savara Reports First Quarter 2018 Financial Results and Provides Business Update
-
Savara Reports First Quarter 2018 Financial Results and Provides Business Update
-
Savara to Host First Quarter 2018 Financial Results and Business Update Conference Call on Wednesday, May 9, 2018
-
Savara to Present at 28th Annual Oppenheimer & Co. Healthcare Conference on March 20th
-
Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
-
Savara (SVRA) Initiates Phase 2a Clinical Study of Molgradex for Treatment of NTM Lung Infection
-
Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection
-
Savara (SVRA) Says Aironite Fails to Meet Primary Endpoint in Indie Phase 2 Clinical Study (Earlier)
-
Aironite Fails to Meet Primary Endpoint in the Indie Phase 2 Clinical Study Conducted by the Heart Failure Clinical Research Network
-
Savara to Host Fourth Quarter & Fiscal Year End 2017 Financial Results and Business Update Conference Call on Wednesday March 14, 2018
-
Savara (SVRA) Says Top Line Results From Aironite Phase 2 Clinical Trial for Treatment of HFpEF to Be Presented at ACC

